Mepsevii® (vestronidase alfa-vjbk) Injection

Mepsevii (vestronidase alfa‑vjbk) is covered only for the FDA‑approved treatment of mucopolysaccharidosis type VII (Sly syndrome) and is not covered for off‑label uses. Coverage requires confirmed diagnosis by deficient beta‑glucuronidase activity or a GUSB gene mutation, prescription by or consultation with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, documentation of meeting applicable safety criteria, and is approved for 12 months at the recommended dose of 4 mg/kg IV every two weeks.

"Treatment of individuals with mucopolysaccharidosis type VII (MPS VII; Sly syndrome) — FDA‑approved indication"

Sign up to see full coverage criteria, indications, and limitations.